Atherosclerosis
Volume 212, Issue 1 , Pages 16-29 , September 2010

Genetic and epigenetic mechanisms and their possible role in abdominal aortic aneurysm

  • Smriti M. Krishna

      Affiliations

    • Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Queensland 4811, Australia
    • ,
  • Anthony E. Dear

      Affiliations

    • ECRU Biotech Laboratory, Monash University, Melbourne, Australia
    • ,
  • Paul E. Norman

      Affiliations

    • School of Surgery, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia 6959, Australia
    • ,
  • Jonathan Golledge

      Affiliations

    • Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Queensland 4811, Australia
    • Corresponding Author InformationCorresponding author at: Vascular Biology Unit, Department of Surgery, School of Medicine, James Cook University, Townsville, Queensland 4811, Australia. Tel.: +61 7 4796 1417; fax: +61 7 4796 1401.

Received 2 December 2009 ,Revised 29 January 2010 ,Accepted 4 February 2010.

References 

  1. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007;128(February (4)):635–638
  2. Desaulniers D, Xiao GH, Lian H, et al. Effects of mixtures of polychlorinated biphenyls, methylmercury, and organochlorine pesticides on hepatic DNA methylation in prepubertal female Sprague–Dawley rats. Int J Toxicol. 2009;28(July–August (4)):294–307
  3. Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia?. J Nutr. 2005;135(January (1)):5–8
  4. Laukkanen MO, Mannermaa S, Hiltunen MO, et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol. 1999;19(September (9)):2171–2178
  5. Turunen MP, Aavik E, Ylä-Herttuala S. Epigenetics and atherosclerosis. Biochim Biophys Acta. 2009;1790(September (9)):886–891
  6. Pons D, Jukema JW. Epigenetic histone acetylation modifiers in vascular remodelling—new targets for therapy in cardiovascular disease. Neth Heart J. 2008;16(1):30–32
  7. Gratama JW, van Leeuwen RB. Abdominal aortic aneurysm: high prevalence in men over 59 years of age with TIA or stroke, a perspective. Abdom Imaging. 2010;35(1):95–98
  8. Chichester Aneurysm Screening Group; Viborg Aneurysm Screening Study; Western Australian Abdominal Aortic Aneurysm Program; Multicentre Aneurysm Screening Study. A comparative study of the prevalence of abdominal aortic aneurysms in the United Kingdom, Denmark, and Australia. J Med Screen. 2001; 8(1):46-50.
  9. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. Br J Surg. 2002;89(March (3)):283–285
  10. The UK Small Aneurysm Trial Participants . Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet. 1998;352:1649–1655
  11. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346(May (19)):1437–1444
  12. Cao P. Comparison of surveillance vs Aortic Endografting for Small Aneurysm Repair (CAESAR) trial: study design and progress. Eur J Vasc Endovasc Surg. 2005;30(September (3)):245–251
  13. Ouriel K. Randomized clinical trials of endovascular repair versus surveillance for treatment of small abdominal aortic aneurysms. J Endovasc Ther. 2009;16(February (Suppl. 1)):I94–105
  14. Annambhotla S, Bourgeois S, Wang X, et al. Recent advances in molecular mechanisms of abdominal aortic aneurysm formation. World J Surg. 2008;32(June (6)):976–986
  15. Wassef M, Upchurch GR, Kuivaniemi H, Thompson RW, Tilson MD. Challenges and opportunities in abdominal aortic aneurysm research. J Vasc Surg. 2007;45(January (1)):192–198
  16. Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res. 2009;83(August (3)):436–443
  17. Henderson EL, Geng YJ, Sukhova GK, et al. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation. 1999;99:96–104
  18. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110(September (5)):625–632
  19. van Vlijmen-van Keulen CJPG, Rauwerda JA. Familial abdominal aortic aneurysm: a systematic review of a genetic background. Eur J Vasc Endovasc Surg. 2002;24(August (2)):105–116
  20. The Aneurysm Consortium . Genome wide association studies: identifying the genes that determine the risk of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2008;36(October (4)):395–396
  21. Larsson E, Granath F, Swedenborg J, Hultgren R. A population-based case-control study of the familial risk of abdominal aortic aneurysm. J Vasc Surg. 2009;49(January (1)):47–50(discussion 1)
  22. Majumder PP, St Jean PL, Ferrell RE, Webster MW, Steed DL. On the inheritance of abdominal aortic aneurysm. Am J Hum Genet. 1991;48(January (1)):164–170
  23. Worrall BB, Foroud T, Brown RD, et al. Genome screen to detect linkage to common susceptibility genes for intracranial and aortic aneurysms. Stroke. 2009;40(January (1)):71–76
  24. Shibamura H, Olson JM, van Vlijmen-Van Keulen C, et al. Genome scan for familial abdominal aortic aneurysm using sex and family history as covariates suggests genetic heterogeneity and identifies linkage to chromosome 19q13. Circulation. 2004 May 4;109(17):2103–2108
  25. Van Vlijmen-Van Keulen CJ, Rauwerda JA, Pals G. Genome-wide linkage in three Dutch families maps a locus for abdominal aortic aneurysms to chromosome 19q13.3. Eur J Vasc Endovasc Surg. 2005;30(July (1)):29–35
  26. Kuivaniemi H, Kyo Y, Lenk G, Tromp G. Genome-wide approach to finding abdominal aortic aneurysm susceptibility genes in humans. Ann N Y Acad Sci. 2006;November (1085):270–281
  27. Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res. 2001;11(December (12)):2115–2119
  28. Baas AF, Medic J, van’t Slot R, de Kovel CG, Zhernakova A, Geelkerken RH, et al. Association of the TGF-beta receptor genes with abdominal aortic aneurysm. Eur J Hum Genet. 2010;18(2):240–244
  29. Massart F, Marini F, Menegato A, et al. Allelic genes involved in artery compliance and susceptibility to sporadic abdominal aortic aneurysm. J Steroid Biochem Mol Biol. 2004;92:413–418
  30. Fatini C, Pratesi G, Sofi F, et al. ACE DD genotype: a predisposing factor for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2005;29(March (3)):227–232
  31. Lucarini L, Sticchi E, Sofi F, et al. ACE and TGFBR1 genes interact in influencing the susceptibility to abdominal aortic aneurysm. Atherosclerosis. 2009;202(January (1)):205–210
  32. Korcz A, Mikolajczyk-Stecyna J, Gabriel M, et al. Angiotensin-converting enzyme (ACE, I/D) gene polymorphism and susceptibility to abdominal aortic aneurysm or aortoiliac occlusive disease. J Surg Res. 2009;153(May (1)):76–82
  33. Jones GT, Harris EL, Phillips LV, van Rij AM. The methylenetetrahydrofolate reductase C677T polymorphism does not associate with susceptibility to abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2005;30(August (2)):137–142
  34. Jones GT, Thompson AR, van Bockxmeer FM, et al. Angiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts. Arterioscler Thromb Vasc Biol. 2008;28(April (4)):764–770
  35. Deguara J, Burnand KG, Berg J, et al. An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms. Hum Mol Genet. 2007 Dec 15;16(December (24)):3002–3007
  36. Jones GT, Phillips VL, Harris EL, Rossaak JI, van Rij AM. Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. J Vasc Surg. 2003 Dec;38(6):1363–1367
  37. Ogata T, Shibamura H, Tromp G, et al. Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg. 2005;41:1036–1042
  38. Hinterseher I, Krex D, Kuhlisch E, et al. Analysis of tissue inhibitor of metalloproteinase-2 gene polymorphisms in a caucasian population with abdominal aortic aneurysms. Zentralbl Chir. 2008;133(August (4)):332–337
  39. Rossaak JI, Van Rij AM, Jones GT, Harris EL. Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms. J Vasc Surg. 2000;31(May (5)):1026–1032
  40. Bown MJ, Lloyd GM, Sandford RM, et al. The interleukin-10-1082 ‘A’ allele and abdominal aortic aneurysms. J Vasc Surg. 2007;46(October (4)):687–693
  41. Ghilardi G, Biondi ML, Battaglioli L, et al. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. J Vasc Surg. 2004;40(November (5)):995–1000
  42. Rasmussen TE, Hallett JW, Tazelaar HD, et al. Human leukocyte antigen class II immune response genes, female gender, and cigarette smoking as risk and modulating factors in abdominal aortic aneurysms. J Vasc Surg. 2002;35(May (5)):988–993
  43. Fatini C, Sofi F, Sticchi E, et al. eNOS G894T polymorphism as a mild predisposing factor for abdominal aortic aneurysm. J Vasc Surg. 2005;42(September (3)):415–419
  44. Strauss E, Waliszewski K, Gabriel M, Zapalski S, Pawlak AL. Increased risk of the abdominal aortic aneurysm in carriers of the MTHFR 677T allele. J Appl Genet. 2003;44(1):85–93
  45. Schillinger M, Exner M, Mlekusch W, et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res. 2002;106(April (2)):131–136
  46. Giusti B, Saracini C, Bolli P, et al. Genetic analysis of 56 polymorphisms in 17 genes involved in methionine metabolism in patients with abdominal aortic aneurysm. J Med Genet. 2008;45(November (11)):721–730
  47. Pannu H, Avidan N, Tran-Fadulu V, Milewicz DM. Genetic basis of thoracic aortic aneurysms and dissections: potential relevance to abdominal aortic aneurysms. Ann N Y Acad Sci. 2006;November (1085):242–255
  48. Milewicz DM, Guo DC, Tran-Fadulu V, et al. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet. 2008;9:283–302
  49. Golledge J, Clancy P, Jones GT, et al. Possible association between genetic polymorphisms in transforming growth factor beta receptors, serum transforming growth factor beta1 concentration and abdominal aortic aneurysm. Br J Surg. 2009;96(June (6)):628–632
  50. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40(February (2)):217–224
  51. Thompson AR, Golledge J, Cooper JA, et al. Sequence variant on 9p21 is associated with the presence of abdominal aortic aneurysm disease but does not have an impact on aneurysmal expansion. Eur J Hum Genet. 2009;17(March (3)):391–394
  52. Elmore JR, Obmann MA, Kuivaniemi H, et al. Identification of a genetic variant associated with abdominal aortic aneurysms on chromosome 3p12.3 by genome wide association. J Vasc Surg. 2009;49(June (6)):1525–1531
  53. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structures of the nucleosome core particle at 2.8A resolution. Nature. 1997;389(September (6648)):251–260
  54. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(May (6990)):457–463
  55. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(August (5532)):1074–1080
  56. Bannister AJ, Kouzarides T. Reversing histone methylation. Nature. 2005;436(August (7054)):1103–1106
  57. McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev. 2001;11:497–504
  58. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell. 2002;108(February (4)):475–487
  59. Ha CH, Wang W, Jhun BS, et al. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J Biol Chem. 2008;283(May (21)):14590–14599
  60. Wang S, Li X, Parra M, et al. Control of endothelial cell proliferation and migration by VEGF signalling to histone deacetylase 7. Proc Natl Acad Sci USA. 2008;105(June (22)):7738–7743
  61. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006;20(June (11)):1405–1428
  62. Tazi J, Bird A. Alternative chromatin structure at CpG islands. Cell. 1990;60(March (6)):909–920
  63. Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res. 2008;102(April (8)):873–887
  64. Dong C, Yoon W, Goldschmidt-Clermont PJ. DNA methylation and atherosclerosis. J Nutr. 2002;132(August (Suppl. 8)):2406S–2409S
  65. Hiltunen MO, Yla-Herttuala S. DNA methylation, smooth muscle cells, and atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23(October (10)):1750–1753
  66. Pascale RM, Simile MM, De Miglio MR, Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-l-methionine. Alcohol. 2002;27(July (3)):193–198
  67. Ikegami K, Ohgane J, Tanaka S, Yagi S, Shiota K. Interplay between DNA methylation, histone modification and chromatin remodelling in stem cells and during development. Int J Dev Biol. 2009;53(2–3):203–214
  68. Fuks F, Hurd PJ, Wolf D, et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem. 2003;278:4035–4040
  69. Reed D, Reed C, Stemmermann G, Hayashi T. Are aortic aneurysms caused by atherosclerosis?. Circulation. 1992;85:205–211
  70. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation. 1997;96(October (7)):2115–2117
  71. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 1999;43(September (4)):985–991
  72. Ying AK, Hassanain HH, Roos CM, et al. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc Res. 2000;46(April (1)):172–179
  73. Choi JH, Nam KH, Kim J, et al. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25(November (11)):2404–2409
  74. Kong X, Fang M, Li P, Fang F, Xu Y. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J Mol Cell Cardiol. 2009;46(March (3)):292–299
  75. Arapoglou V, Kondi-Pafiti A, Rizos D, et al. The influence of total plasma homocysteine and traditional atherosclerotic risk factors on degree of abdominal aortic aneurysm tissue inflammation. Vasc Endovascular Surg. 2009;43(October–November (5)):473–479
  76. Sato N, Maehara N, Su GH, Goggins M. Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst. 2003;95(February (4)):327–330
  77. Jayaraman G, Srinivas R, Duggan C, et al. p300/cAMP-responsive element-binding protein interactions with ets-1 and ets-2 in the transcriptional activation of the human stromelysin promoter. J Biol Chem. 1999;274(June (24)):17342–17352
  78. Wild A, Ramaswamy A, Langer P, et al. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J Clin Endocrinol Metab. 2003;88(March (3)):1367–1373
  79. Chan GC, Fish JE, Mawji IA, et al. Epigenetic basis for the transcriptional hypo responsiveness of the human inducible nitric oxide synthase gene in vascular endothelial cells. J Immunol. 2005;175(September (6)):3846–3861
  80. Chan Y, Fish JE, D’Abreo C, et al. The cell-specific expression of endothelial nitric-oxide synthase: a role for DNA methylation. J Biol Chem. 2004;279(August (33)):35087–35100
  81. White GP, Watt PM, Holt BJ, Holt PG. Differential patterns of methylation of the IFN-gamma promoter at CpG and non-CpG sites underlie differences in IFN-gamma gene expression between human neonatal and adult CD45RO-T cells. J Immunol. 2002;168(March (6)):2820–2827
  82. Takei S, Fernandez D, Redford A, Toyoda H. Methylation status of 5′-regulatory region of tumour necrosis factor alpha gene correlates with differentiation stages of monocytes. Biochem Biophys Res Commun. 1996;220(March (3)):606–612
  83. Hellebrekers DM, Castermans K, Vire E, et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006;66(November (22)):10770–10777
  84. Armenante F, Merola M, Furia A, Palmieri M. Repression of the IL-6 gene is associated with hypermethylation. Biochem Biophys Res Commun. 1999;258(May (3)):644–647
  85. Dandrea M, Donadelli M, Costanzo C, Scarpa A, Palmieri M. MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines. Nucleic Acids Res. 2009;(September):
  86. Osada H, Tatematsu Y, Sugito N, Horio Y, Takahashi T. Histone modification in the TGF-beta-RII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines. Mol Carcinog. 2005;44(December (4)):233–241
  87. Lin XH, Guo C, Gu LJ, Deuel TF. Site-specific methylation inhibits transcriptional activity of platelet-derived growth factor A-chain promoter. J Biol Chem. 1993;268(August (23)):17334–17340
  88. Kim J, Kim JY, Song KS, et al. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta. 2007;1772(January (1)):72–80
  89. Hastings NE, Simmers MB, McDonald OG, Wamhoff BR, Blackman BR. Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol Cell Physiol. 2007;293(December (6)):C1824–C1833
  90. Liu C, Xu D, Sjoberg J, et al. Transcriptional regulation of 15-lipoxygenase expression by promoter methylation. Exp Cell Res. 2004;297(July (1)):61–67
  91. Devlin AM, Singh R, Wade RE, et al. Hypermethylation of Fads2 and altered hepatic fatty acid and phospholipid metabolism in mice with hyper-homocysteinemia. J Biol Chem. 2007;282(December (51)):37082–37090
  92. Chen Z, Karaplis AC, Ackerman SL, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyper-homocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet. 2001;10(March (5)):433–443
  93. Schroeder M, Mass MJ. CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumour suppressor gene. Biochem Biophys Res Commun. 1997;235(June (2)):403–406
  94. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26(December (12)):2605–2613
  95. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet. 2005;365(April–May (9470)):1577–1589
  96. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994–2001. Circulation. 2009;119(April (16)):2202–2208
  97. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110(July (1)):16–21
  98. Bergoeing MP, Arif B, Hackmann AE, et al. Cigarette smoking increases aortic dilatation without affecting matrix metalloproteinase-9 and -12 expression in a modified mouse model of aneurysm formation. J Vasc Surg. 2007;45(June (6)):1217–1227
  99. Takagi H, Umemoto T. Smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway. Med Hypotheses. 2005;64(6):1117–1119
  100. Zhu J, Kilty I, Granger H, et al. Gene expression and immunolocalization of 15-lipoxygenase isozymes in the airway mucosa of smokers with chronic bronchitis. Am J Respir Cell Mol Biol. 2002;27(December (6)):666–677
  101. Bengtsson H, Bergqvist D, Sternby NH. Increasing prevalence of abdominal aortic aneurysms. A necropsy study. Eur J Surg. 1992;158:19–23
  102. Issa JP. Aging DNA methylation and cancer. Crit Rev Oncol Hematol. 1999;32(September (1)):31–43
  103. Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7(August (4)):536–540
  104. Wilson VL, Jones PA. DNA methylation decreases in aging but not in immortal cells. Science. 1983;220(June (4601)):1055–1057
  105. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141–196
  106. Hiltunen MO, Turunen MP, Hakkinen TP, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002;7(February (1)):5–11
  107. Calvanese V, Lara E, Kahn A, Fraga MF. The role of epigenetics in aging and age-related diseases. Ageing Res Rev. 2009;8(October (4)):268–276
  108. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26(May (5)):987–994
  109. McCormick ML, Gavrila D, Weintraub NL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2007;27(March (3)):461–469
  110. Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodelling but differentially regulate NF-kappaB activation and pro-inflammatory cytokine release in alveolar epithelial cells. FASEB J. 2004;18:1897–1899
  111. Pons D, de Vries FR, van den Elsen PJ, et al. Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J. 2009;30(February (3)):266–277
  112. Corwin EJ. The concept of epigenetics and its role in the development of cardiovascular disease: commentary on “new and emerging theories of cardiovascular disease. Biol Res Nurs. 2004;6(July (1)):11–16(discussion 21–3)
  113. Jang TJ, Kim DI, Shin YM, Chang HK, Yang CH. p16(INK4a) Promoter hyper-methylation of non-tumorous tissue adjacent to gastric cancer is correlated with glandular atrophy and chronic inflammation. Int J Cancer. 2001;93(September (5)):629–634
  114. Kang GH, Lee HJ, Hwang KS, et al. Aberrant CpG island hyper-methylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol. 2003;163(October (4)):1551–1556
  115. Teitell M, Richardson B. DNA methylation in the immune system. Clin Immunol. 2003;109(October (1)):2–5
  116. Hodge DR, Xiao W, Clausen PA, et al. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem. 2001;276(October (43)):39508–39511
  117. Hodge DR, Peng B, Cherry JC, et al. Interleukin 6 supports the maintenance of p53 tumour suppressor gene promoter methylation. Cancer Res. 2005;65(June (11)):4673–4682
  118. Stenvinkel P, Karimi M, Johansson S, et al. Impact of inflammation on epigenetic DNA methylation—a novel risk factor for cardiovascular disease?. J Intern Med. 2007;261(May (5)):488–499
  119. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signalling, is frequently silenced by methylation in multiple myeloma. Blood. 2003;101(April (7)):2784–2788
  120. Williams KT, Garrow TA, Schalinske KL. Type I diabetes leads to tissue-specific DNA hypo-methylation in male rats. J Nutr. 2008;138(November (11)):2064–2069
  121. Yi P, Melnyk S, Pogribna M, et al. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypo-methylation. J Biol Chem. 2000;275(September (38)):29318–29323
  122. James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA. Elevation in S-adenosylhomocysteine and DNA hypo-methylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr. 2002;132(August (Suppl. 8)):2361S–2366S
  123. Sharma P, Kumar J, Garg G, et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol. 2008;27(July (7)):357–365
  124. Ulrey CL, Liu L, Andrews LG, Tollefsbol TO. The impact of metabolism on DNA methylation. Hum Mol Genet 2005;April (14 Spec No. 1):R139–47.
  125. Castro R, Rivera I, Struys EA, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypo-methylation in vascular disease. Clin Chem. 2003;49(August (8)):1292–1296
  126. Lund G, Andersson L, Lauria M, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem. 2004 Jul 9;279(28):29147–29154
  127. Moat SJ, Lang D, McDowell IF, et al. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem. 2004;15(February (2)):64–79
  128. Moroz P, Le MT, Norman PE. Homocysteine and abdominal aortic aneurysms. ANZ J Surg. 2007;77(May (5)):329–332
  129. Sofi F, Marcucci R, Giusti B, et al. High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thromb Haemost. 2005;94(November (5)):1094–1098
  130. Brunelli T, Prisco D, Fedi S, et al. High prevalence of mild hyper-homocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg. 2000;32(September (3)):531–536
  131. Peeters AC, van Landeghem BA, Graafsma SJ, et al. Low vitamin B6, and not plasma homocysteine concentration, as risk factor for abdominal aortic aneurysm: a retrospective case–control study. J Vasc Surg. 2007;45(April (4)):701–705
  132. Neves MF, Endemann D, Amiri F, et al. Small artery mechanics in hyper-homocysteinemic mice: effects of angiotensin II. J Hypertens. 2004;22(May (5)):959–966
  133. Bortolotto LA, Safar ME, Billaud E, et al. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension. 1999;34(October (4 Pt 2)):837–842
  134. Prall AK, Longo GM, Mayhan WG, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002;35(May (5)):923–929
  135. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23(March (3)):483–488
  136. Nozell S, Ma Z, Wilson C, Shah R, Benveniste EN. Class II major histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9 gene expression. J Biol Chem. 2004;279(September (37)):38577–38589
  137. Yan C, Wang H, Toh Y, Boyd DD. Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J Biol Chem. 2003;278(January (4)):2309–2316
  138. Pender SL, Quinn JJ, Sanderson IR, MacDonald TT. Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. Am J Physiol Gastrointest Liver Physiol. 2000;279(November (5)):G918–G924
  139. Ailenberg M, Silverman M. Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression. Biochem Biophys Res Commun. 2002;298(October (1)):110–115
  140. Chang S, Young BD, Li S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006;126(July (2)):321–334
  141. Vinh A, Gaspari TA, Liu HB, et al. A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J Vasc Res. 2008;45(2):143–152
  142. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab. 2007;8:383–393
  143. Van Wagoner DR, Nattel S. Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy. J Mol Cell Cardiol. 2008;45(December (6)):707–708
  144. Wang L, de Zoeten EF, Greene MI, Hancock WW. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov. 2009;8(December (12)):969–981
  145. Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A. Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem. 2007;282(September (39)):28408–28418
  146. Okamoto H, Fujioka Y, Takahashi A, et al. Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb. 2006;13:183–191
  147. Lee TM, Lin MS, Chang NC. Inhibition of histone deacetylase on ventricular remodelling in infracted rats. Am J Physiol Heart Circ Physiol. 2007;293(August (2)):H968–H977
  148. Liu F, Levin MD, Petrenko NB, et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol. 2008;45(December (6)):715–723
  149. Granger A, Abdullah I, Huebner F, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 2008;22(October (10)):3549–3560
  150. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumour suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65(July (14)):6305–6311
  151. Lin X, Asgari K, Putzi MJ, et al. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 2001;61:8611–8616
  152. Gomeza D JG, Michela JB, Vranckxa R. J005 Genetic and non-genetic forms of aneurysms of the human ascending aorta share activation and over expression of Smad2: putative implication of epigenetic mechanisms. Arch Cardiovas Dis 2009;102(March (1)):S104.
  153. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res. 2007;61(May (5 Pt 2)):24R–29R
  154. Wang S, Olson EN. AngiomiRs—key regulators of angiogenesis. Curr Opin Genet Dev. 2009;19(June (3)):205–211
  155. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100):ra81
  156. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(August (2)):261–271

PII: S0021-9150(10)00106-1

doi: 10.1016/j.atherosclerosis.2010.02.008

Atherosclerosis
Volume 212, Issue 1 , Pages 16-29 , September 2010

Article Tools

* Image Usage & Resolution